This message was sent to ##Email##
|
|
|
|
|
| |
Cancer Programs - AJCC
The decision to delay implementation of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, Eighth Edition to Jan. 1, 2018, has provided the AJCC with an opportunity to take a careful look at the way it has traditionally communicated cancer staging. Since the manual was published last fall, the AJCC has worked with the surveillance community, the pathology community and clinical decision support software developers to take a more critical look at the content and make improvements and clarifications that will help everyone who uses this information including the registrar, clinician and the software developer.
As part of this effort, the AJCC decided to validate and update the Eighth Edition breast cancer staging system using an additional year’s worth of data from the National Cancer Database (NCDB). The AJCC Breast Expert Panel has recommended providing two breast cancer Prognostic Stage tables based on further analysis of the NCDB data.
The Clinical Prognostic Stage Group will be used to assign stage for all patients based on history, physical examination, imaging studies and relevant biopsies. The Pathological Prognostic Stage Group will be used to assign stage for patients who have surgical resection as the initial treatment of their cancer before any systemic or radiation therapy. The Breast Expert Panel also recommended clinical, pathological and post-therapy data elements that cancer registries should record.
As science continues to evolve, the AJCC is committed to validating and incorporating important updates and communicating them transparently. We understand the burden that these changes place on those who purchased the first printing of the manual. To this end, the entire breast cancer chapter of the manual is now available through the AJCC website, and replacement pages for all updates and corrections made to the entire manual will be available in December 2017. Future printings of the Staging Manual will include the updated breast chapter as well as other minor updates and corrections issued to date.
Please visit cancerstaging.org for education and regular updates to the Eighth Edition.
READ MORE
Oncology Nurse Advisor
The U.S. Food and Drug Administration expanded the approval of vemurafenib to include the treatment of BRAF V600 mutation-positive Erdheim-Chester disease, Roche announced in a news release.
ECD is a rare blood cancer — estimates state fewer than 500 cases in the United States — characterized by slow growth and increased production of histiocytes, a class of white blood cell. Approximately 50 percent of patients with ECD are BRAF V600 mutation-positive.
READ MORE
ACS Quality Programs
The 2018 ACS Quality and Safety Conference: Partners in Quality will be held in Orlando, July 21-24. This education program brings health care professionals together to discuss and apply current knowledge pertaining to national and local quality initiatives in the field of surgery. Attendees will learn techniques to manage, analyze, and interpret data to make a positive impact at their facilities. The Cancer Programs are excited to be included in this one-of-a-kind conference and encourage staff working in CoC and/or NAPBC-accredited programs to submit an abstract for a podium or poster presentation. The abstract should relate to surgical quality improvement initiatives including the development, implementation, or validation of best practices within your accredited program. Abstracts for this conference will be accepted until Jan. 26, 2018. (Please note: This is not the 2018 Cancer Program Annual Conference that will be held in the fall of 2018. Information on the 2018 Cancer Programs Annual Conference will be available in early January, 2018.)
READ MORE
Medical News Today
Warfarin is a type of anticoagulant, or blood thinner, that helps to prevent the formation of blood clots. It works by inhibiting the body's production of vitamin K, which is needed to form blood clots.
The medication is most commonly prescribed to people who have experienced heart attack, stroke, deep vein thrombosis and other conditions caused by blood clots. Warfarin may also be prescribed for people at increased risk of developing blood clots, including individuals with arrhythmia, or irregular heartbeat, and those with prosthetic heart valves.
READ MORE
|
Promoted by
|
|
|
|
 |
American College of Surgeons
American College of Surgeons (ACS) Cancer Programs is pleased to announce that it is accepting applications for the National Accreditation Program for Rectal Cancer (NAPRC). The NAPRC was developed to ensure that rectal cancer patients receive appropriate care following a multidisciplinary approach. Programs will be evaluated on the standards and metrics outlined in The National Accreditation Program for Rectal Cancer Standards Manual 2017 (revised October 2017).
READ MORE
The JAMA Network
Determining the microsatellite instability status of colorectal carcinoma and other tumor types has recently increased in importance for patient management and prevention strategies. High-level MSI/deficient mismatch repair (widely used alternative terminologies) has long been known to be a hallmark of Lynch syndrome. The identification of this small subset of patients has major implications for prevention in blood relatives and for avoiding metachronous tumors in patients who have a first Lynch-associated tumor.
READ MORE
Rice University via Phys.org
Researchers investigating ways to deliver high doses of cancer-killing drugs inside tumors have shown they can use a laser and light-activated gold nanoparticles to remotely trigger the release of approved cancer drugs inside cancer cells in laboratory cultures.
The study by researchers at Rice University and Northwestern University Feinberg School of Medicine appears online in Early Edition of the Proceedings of the National Academy of Sciences. It employed gold nanoshells to deliver toxic doses of two drugs—lapatinib and docetaxel—inside breast cancer cells. The researchers showed they could use a laser to remotely trigger the particles to release the drugs after they entered the cells.
READ MORE
University of Michigan via Medical Xpress
Honeycomb-like arrays of tiny, lab-grown cancers could one day help doctors zero in on individualized treatments for ovarian cancer, an unpredictable disease that kills more than 14,000 women each year in the United States alone.
A team of researchers has devised a process that can grow hundreds of cultured cell masses, called spheroids, from just a few tumor cells derived from a patient. Grown in a U-M-developed structure called a 384-hanging drop array, each spheroid is encased in a tiny droplet of a special culturing medium. This 3-D method yields cells that grow and multiply just as they would inside the body.
READ MORE
| |
PRODUCT SHOWCASE | Advertisement
|
 |
|
Enjoy our journals? There’s an app for those! Journals such as those from the American Cancer Society ™, Journal of Surgical Oncology, Cancer Science and more are now available for your iPad and iPhone. Sample issues and abstracts, as well as open articles, can be accessed for free. A subscription to the journal is required to read the full text. Click here to learn more!
|
|
The JAMA Network
Accumulating evidence indicates that tumor-infiltrating lymphocytes (TILs) are associated with clinical outcomes and may predict the efficacy of chemotherapy and human epidermal growth factor receptor 2 targeted therapy in patients with HER2-positive breast cancer. To investigate the role of TILs, particularly cytotoxic CD8+ T cells, in the prediction of outcomes in patients with HER2-positive metastatic breast cancer randomized to an antibody-based vs a small molecule-based anti-HER2 therapy.
READ MORE
University of Texas at Dallas via Medical Xpress
Dr. Jung-Mo Ahn, associate professor of chemistry and biochemistry at The University of Texas at Dallas, has designed a small molecule that could help breast cancer patients for whom current treatments no longer work.
In a paper published recently in the online journal eLife, Ahn and his colleagues describe their approach to designing the molecule as well as experiments that show its effectiveness at stopping the progression of treatment-resistant breast cancer cells in isolation and in an animal model.
READ MORE
 |
|
Novodiax is soon bringing to market 10-minute fast, sensitive and simple Immunoassay (IHC) kits for in vitro diagnostic use to address unmet needs in the intraoperative surgical oncology sector. Learn More
|
|
Cancer Network via Modern Medicine
The immune checkpoint inhibitor pembrolizumab demonstrated antitumor activity in a small trial of patients with advanced cervical cancer. The agent had a similar toxicity profile to that seen in other malignancies. Though patients who present with localized cervical cancer have a good prognosis, this is not the case in those who present with advanced disease.
READ MORE
University of Michigan via Medical Xpress
Even 20 years after a diagnosis, women with a type of breast cancer fueled by estrogen still face a substantial risk of cancer returning or spreading, according to a new analysis from an international team of investigators published in the New England Journal of Medicine.
Standard treatment for estrogen receptor-positive, or ER-positive, breast cancer includes five years of the endocrine-based treatments tamoxifen or aromatase inhibitors, both of which are a taken daily as a pill.
READ MORE
 |
|
Doctors Without Borders/Médecins Sans Frontières (MSF) is actively recruiting general and trauma surgeons with experience in emergency obstetrics for international missions in developing countries. Learn more.
|
|
|
Missed last week's issue? See which articles your colleagues read most.
|
Don't be left behind. Click here to see what else you missed.
|
|
|
|
The Brief
Connect with AJCC
Connect with CoC
Connect with NAPBC
Recent Issues | Subscribe | Unsubscribe | Advertise | Web Version
Colby Horton, Vice President of Publishing, 469-420-2601 | Download media kit
Ashley Harrington, Senior Content Editor, 469-420-2642 | Contribute news
Disclaimer: The Brief is a digest of news selected for the Commission on Cancer (CoC) and the National Accreditation Program for Breast Centers (NAPBC), both quality programs of the American College of Surgeons, from thousands of sources by the editors of MultiBriefs, an independent organization that also manages and sells advertising. The CoC and NAPBC do not endorse any of the advertised products and services. Opinions expressed in the articles are those of the author and not of the American College of Surgeons, the CoC and the NAPBC.
American College of Surgeons
633 N Saint Clair Street | Chicago, IL, 60611-3211 | 800-621-4111 | Contact Us
Learn how to add us to your safe sender list so our emails get to your inbox. |
|
| |
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
